



17
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 011823-004920US
Client Ref. No.: PDL0049-20

Box Sequence
Box 2327
Arlington, VA 22202

On Dec 4, 2002

TOWNSEND and TOWNSEND and CREW, LLP

By: Paula Paula Hurley

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Weiner et al.

Application No.: 09/618,380

Filed: July 18, 2000

For: HUMANIZED ANTIBODIES
AGAINST CD3

Examiner: L. Helms

Art Unit: 1642

PRELIMINARY AMENDMENT

Match and Return

Box Sequence
Box 2327
Arlington, VA 22202

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants now submit a Substitute Sequence Listing to correct typographical errors identified in the paper copy of the Sequence Listing submitted July 31, 2000, and CRF version of sequence listing referenced in preliminary amendment and communication filed October 16, 2001.

Please find enclosed a Substitute Sequence Listing in the paper and computer readable format to replace the original paper and CRF Sequence Listings filed for this application on July 31, 2000 and October 16, 2001, respectively.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

OK
TO
NOT
ENTER
LQ
9/10/03

19/12